<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006009</article-id><article-id pub-id-type="pmc">PMC11859419</article-id><article-id pub-id-type="doi">10.3390/ph18020194</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-18-00194</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>New UB006 Derivatives With Higher Solubility and Cytotoxic Activity in Ovarian Cancer Cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Reina</surname><given-names>Marc</given-names></name><xref rid="af1-pharmaceuticals-18-00194" ref-type="aff">1</xref><xref rid="af2-pharmaceuticals-18-00194" ref-type="aff">2</xref><xref rid="af3-pharmaceuticals-18-00194" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1479-3668</contrib-id><name><surname>Ariza</surname><given-names>Xavier</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-pharmaceuticals-18-00194" ref-type="aff">2</xref><xref rid="af3-pharmaceuticals-18-00194" ref-type="aff">3</xref><xref rid="af4-pharmaceuticals-18-00194" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Serra</surname><given-names>Dolors</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-pharmaceuticals-18-00194" ref-type="aff">1</xref><xref rid="af3-pharmaceuticals-18-00194" ref-type="aff">3</xref><xref rid="af4-pharmaceuticals-18-00194" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9379-2577</contrib-id><name><surname>Garcia</surname><given-names>Jordi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-pharmaceuticals-18-00194" ref-type="aff">2</xref><xref rid="af3-pharmaceuticals-18-00194" ref-type="aff">3</xref><xref rid="af4-pharmaceuticals-18-00194" ref-type="aff">4</xref><xref rid="c1-pharmaceuticals-18-00194" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4244-4673</contrib-id><name><surname>Herrero</surname><given-names>Laura</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af1-pharmaceuticals-18-00194" ref-type="aff">1</xref><xref rid="af3-pharmaceuticals-18-00194" ref-type="aff">3</xref><xref rid="af4-pharmaceuticals-18-00194" ref-type="aff">4</xref><xref rid="c1-pharmaceuticals-18-00194" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Ammazzalorso</surname><given-names>Alessandra</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-18-00194"><label>1</label>Department of Biochemistry and Physiology, School of Pharmacy and Food Sciences, Universitat de Barcelona, E-08028 Barcelona, Spain</aff><aff id="af2-pharmaceuticals-18-00194"><label>2</label>Department of Inorganic and Organic Chemistry, School of Chemistry, Universitat de Barcelona, E-08028 Barcelona, Spain</aff><aff id="af3-pharmaceuticals-18-00194"><label>3</label>Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, E-08028 Barcelona, Spain</aff><aff id="af4-pharmaceuticals-18-00194"><label>4</label>Centro de Investigaci&#x000f3;n Biom&#x000e9;dica en Red (CIBER) de Fisiopatolog&#x000ed;a de la Obesidad y Nutrici&#x000f3;n (CIBEROBN), Instituto de Salud Carlos III, E-28029 Madrid, Spain</aff><author-notes><corresp id="c1-pharmaceuticals-18-00194"><label>*</label>Correspondence: <email>jordigarciagomez@ub.edu</email> (J.G.); <email>lherrero@ub.edu</email> (L.H.)</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>18</volume><issue>2</issue><elocation-id>194</elocation-id><history><date date-type="received"><day>07</day><month>1</month><year>2025</year></date><date date-type="rev-recd"><day>24</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background/Objectives: The compound (&#x000b1;)-<bold>UB006</bold> ((4SR,5SR)-4-(hydroxymethyl)-3-methylene-5-octyldihydrofuran-2(3H)-one) is a promising anti-cancer molecule. The enantiomer (&#x02013;)-<bold>UB006</bold> displays a potent cytotoxic effect in several tumor cell lines, particularly the ovarian cancer OVCAR-3 cell line, with a 40-fold increase in potency compared with the fatty acid synthase (FAS) inhibitor C75. Furthermore, in vivo, (&#x02013;)-<bold>UB006</bold> reduced the tumor burden in neuroblastoma xenografts. This effect was attributed to FAS inhibition and upregulation of apoptotic markers. However, CoA adducts of UB006 presented low solubility. Methods: We synthesized several (&#x000b1;)-<bold>UB006</bold> derivatives by elongating the carbon chain of the primary alcohol and/or by adding hydroxyl groups with the aim of finding more potent and soluble anti-cancer compounds. Results: Our results showed a decrease in cytotoxicity when the carbon chain was elongated by more than two carbons. However, ethyl or propyl polyhydroxylated four-branched compounds showed an increased or maintained potency and solubility. The most promising compound was (&#x000b1;)-<bold>UB035</bold> (IC50: 2.1 &#x000b1; 0.2 &#x000b5;M), with a 2.5-fold increase in cytotoxicity in the OVCAR-3 cell line and a &#x0003e;4-fold increase in solubility (&#x0003e;2 mM) compared with (&#x000b1;)-<bold>UB006</bold>.</p></abstract><kwd-group><kwd>UB006</kwd><kwd>fatty acid synthase</kwd><kwd>cytotoxicity</kwd><kwd>cancer</kwd></kwd-group><funding-group><award-group><funding-source>MICIN/AEI/FEDER</funding-source><award-id>PID2020-114953RB-C21</award-id></award-group><award-group><funding-source>MICIU/AEI/10.13039/501100011033</funding-source><award-id>PID2023-148783OB-I00</award-id></award-group><award-group><funding-source>CIBEROBN</funding-source><award-id>FEDER/UE, CB06/03/0001</award-id></award-group><award-group><funding-source>Government of Catalonia</funding-source><award-id>2021SGR00367</award-id></award-group><award-group><funding-source>FPU doctoral fellowship, MICIN/AEI</funding-source><award-id>2021 FI_B 00572</award-id></award-group><funding-statement>This study was supported by grant PID2020-114953RB-C21 to L.H. and D.S., funded by MICIN/AEI/FEDER, grant PID2023-148783OB-I00 to L.H., funded by MICIU/AEI/10.13039/501100011033, grant FEDER/UE, CB06/03/0001 to L.H., funded by CIBEROBN, grant 2021SGR00367 to L.H., funded by the Government of Catalonia, and 2021 FI_B 00572 (FPU doctoral fellowship, MICIN/AEI) to M.R.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-18-00194"><title>1. Introduction</title><p>Fatty acid synthase (FAS) is a pivotal enzyme in de novo fatty acid synthesis that plays a key role in fueling the enhanced lipid requirements of rapidly proliferating cancer cells. Driven by these observations, FAS inhibition constitutes an attractive strategy to disrupt these vital processes and selectively impede tumor progression [<xref rid="B1-pharmaceuticals-18-00194" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceuticals-18-00194" ref-type="bibr">2</xref>]. Among different alternatives, <bold>C75</bold> and <bold>UB006</bold> share comparable biological targets that underscore their potential as FAS inhibitors and inducers of apoptosis in cancer cells [<xref rid="B2-pharmaceuticals-18-00194" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceuticals-18-00194" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-18-00194" ref-type="bibr">4</xref>]. Specifically, <bold>C75</bold> binds to the active site of FAS, interfering with its catalytic activity and inhibiting the conversion of acetyl-CoA and malonyl-CoA to long-chain fatty acids [<xref rid="B5-pharmaceuticals-18-00194" ref-type="bibr">5</xref>], thus reducing mitochondrial respiration and ATP production. This interference not only disrupts the cellular production of lipids necessary for membrane integrity and signaling but also prevents the activation of downstream signaling cascades, such as AMP-activated protein kinase [<xref rid="B6-pharmaceuticals-18-00194" ref-type="bibr">6</xref>], and other apoptotic regulators, including members of the Bcl-2 protein family [<xref rid="B7-pharmaceuticals-18-00194" ref-type="bibr">7</xref>] and caspases [<xref rid="B8-pharmaceuticals-18-00194" ref-type="bibr">8</xref>], and inhibits PI3K-mTORC1 [<xref rid="B9-pharmaceuticals-18-00194" ref-type="bibr">9</xref>]. In addition, neuroblastoma xenografts treated with <bold>UB006</bold> showed a reduction in cell proliferation and an increase in neural differentiation [<xref rid="B4-pharmaceuticals-18-00194" ref-type="bibr">4</xref>]. This dual impact on lipid homeostasis and cellular energy dynamics aligns <bold>C75</bold> and <bold>UB006</bold> as compounds with overlapping molecular targets, suggesting a commonality in their mechanisms of action in the pursuit of selectively targeting cancer cells and hindering their proliferative potential.</p><p>The compound <bold>C75</bold> also acts centrally in the hypothalamus, specifically on neurons that regulate feeding behavior, altering their sensitivity to peripheral signals, such as the fasting-induced hormone ghrelin [<xref rid="B10-pharmaceuticals-18-00194" ref-type="bibr">10</xref>]. This alteration in neural signaling results in reduced food intake and increased energy expenditure. However, we previously showed that this effect was only observed with the (+)-<bold>C75</bold> enantiomer due to its inhibitory effect on carnitine palmitoyltransferase 1, a key enzyme involved in mitochondrial fatty oxidation [<xref rid="B5-pharmaceuticals-18-00194" ref-type="bibr">5</xref>].</p><p>Solubility is a key physicochemical property for the success of any drug candidate, affecting significantly both in vivo and in vitro assays. The compound <bold>C75</bold> is considered insoluble in water and presents low solubility in basic aqueous media (&#x0003c;0.1 mg/mL) [<xref rid="B11-pharmaceuticals-18-00194" ref-type="bibr">11</xref>] due to its lipophilic nature. Unfortunately, the requirement for co-solvents may compromise cell viability in vitro and limit drug success in vivo. Among different small molecule alternatives, <bold>C75</bold> and <bold>UB006</bold> show promising anti-cancer properties [<xref rid="B2-pharmaceuticals-18-00194" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceuticals-18-00194" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceuticals-18-00194" ref-type="bibr">4</xref>]. However, we have previously reported that both <bold>C75</bold> and <bold>UB006</bold> require a solution containing 10% DMSO plus 20% Kolliphor<sup>&#x000ae;</sup> [<xref rid="B12-pharmaceuticals-18-00194" ref-type="bibr">12</xref>], thus limiting their use in aqueous environments. Therefore, there is a need to develop anti-cancer analogs with a higher solubility. The present study describes a novel approach in the synthesis of <bold>UB006</bold> analogues. Our focus centered on the rational design and synthesis of <bold>UB006</bold> derivatives with the overarching goal of improving their therapeutic potential. Analogues were systematically engineered to enhance cytotoxicity and FAS inhibition and optimize the pharmacokinetic properties. We primarily developed stereoisomeric mixtures of the analogues, as the materials required for their synthesis were more readily available. The most promising compound was (&#x000b1;)-<bold>UB035</bold>, which showed enhanced cytotoxic effects against the cancer cell line OVCAR-3 and was more soluble than (&#x000b1;)-<bold>UB006</bold>.</p></sec><sec sec-type="results" id="sec2-pharmaceuticals-18-00194"><title>2. Results and Discussion</title><sec id="sec2dot1-pharmaceuticals-18-00194"><title>2.1. Synthesis of <italic toggle="yes"><bold>UB006</bold></italic> and Its Novel Derivatives</title><p>A series of UB006 analogues (<xref rid="pharmaceuticals-18-00194-f001" ref-type="fig">Figure 1</xref>, <xref rid="pharmaceuticals-18-00194-t001" ref-type="table">Table 1</xref>) with a modified hydroxymethyl chain was synthesized, and their activities were tested.</p><list list-type="simple"><list-item><p>Synthesis of (&#x000b1;)-<bold>UB006</bold></p></list-item></list><p>An improved method for (&#x000b1;)-<bold>UB006</bold> synthesis was achieved. First, an efficient acyl radical addition of nonanal to dimethyl maleate using Co(II) as a catalyst produced adduct (&#x000b1;)-<bold>2</bold> with a yield of 96% [<xref rid="B13-pharmaceuticals-18-00194" ref-type="bibr">13</xref>]. The ketone group was selectively reduced to alcohol with NaBH<sub>4</sub> and then lactonized in situ to a mixture of cis and trans isomeric lactones under an acidic medium. This mixture was isomerized to produce the more stable trans isomer through treatment with base (1,8-diazabicyclo(5.4.0)undec-7-ene; DBU) under anhydrous conditions to produce &#x0a769;-butyrolactone (&#x000b1;)-trans-<bold>3</bold> as a racemic mixture. The methyl ester was then hydrolyzed in basic media, and the carboxylic compound (&#x000b1;)-trans-<bold>4</bold> was selectively reduced to the corresponding alcohol (&#x000b1;)-trans-<bold>7</bold> using borane-mediated reduction, leaving the lactone functionality intact (<xref rid="pharmaceuticals-18-00194-sch001" ref-type="fig">Scheme 1</xref>). A key step in the sequence was the &#x003b1;-methylenation of the resulting lactone, which was successfully achieved through exposure to MMC (Greene&#x02019;s procedure) [<xref rid="B14-pharmaceuticals-18-00194" ref-type="bibr">14</xref>] to yield (&#x000b1;)-<bold>UB006</bold>.</p><p>Aldehyde (&#x000b1;)-trans-<bold>8</bold> was used as the starting material for the synthesis of the new compounds <bold>UB032</bold>, <bold>UB033</bold>, <bold>UB034</bold>, <bold>UB035</bold>, and <bold>UB036</bold> (<xref rid="pharmaceuticals-18-00194-sch002" ref-type="fig">Scheme 2</xref>). This compound was easily obtained through Swern oxidation of primary alcohol (&#x000b1;)-trans-<bold>7</bold>.</p><list list-type="simple"><list-item><p>Synthesis of <bold>UB031</bold></p></list-item></list><p>After a failed attempt to obtain alcohol (&#x000b1;)-trans-<bold>6</bold> through controlled addition of MeMgBr to (&#x000b1;)-trans-<bold>8</bold> at a low temperature, we finally obtained (&#x000b1;)-trans-<bold>6</bold> in a three-step sequence. First, we transformed compound (&#x000b1;)-trans-<bold>4</bold> into its corresponding Weinreb amide (&#x000b1;)-trans-<bold>5</bold>. Then, careful addition of MeMgBr at &#x02212;20 &#x000b0;C provided the expected methyl ketone in crude form, which was selectively reduced in situ to the desired alcohol (&#x000b1;)-trans-<bold>6</bold> as a mixture of stereoisomers via NaBH<sub>4</sub> treatment (<xref rid="pharmaceuticals-18-00194-sch001" ref-type="fig">Scheme 1</xref>). Synthesis of <bold>UB031</bold> was finally achieved using two-step &#x003b1;-methylenation of the resulting lactone, according to Greene&#x02019;s procedure. <xref rid="pharmaceuticals-18-00194-sch003" ref-type="fig">Scheme 3</xref> shows the two strategies used for methylenation (MMC or CO<sub>2</sub>/LDA) and the newly synthesized &#x003b1;-methylenebutyrolactones.</p><list list-type="simple"><list-item><p>Synthesis of <bold>UB032</bold></p></list-item></list><p>N-methylephedrine-catalyzed addition of ZnEt<sub>2</sub> to aldehyde (&#x000b1;)-trans-<bold>8</bold> according to the classical Soai procedure produced the expected alcohol (&#x000b1;)-trans-<bold>9</bold> but with a moderate yield [<xref rid="B15-pharmaceuticals-18-00194" ref-type="bibr">15</xref>]. An alternative Grignard reaction using ethylmagnesium bromide was unable to yield the desired outcome and was much less selective. Finally, the two-step &#x003b1;-methylenation of the resulting lactone, first introducing an &#x003b1;-carboxylic acid and then the &#x003b1;-methylene group, produced the desired product, <bold>UB032</bold>.</p><list list-type="simple"><list-item><p>Synthesis of <bold>UB033</bold></p></list-item></list><p>The addition of 1-hexynyl lithium to aldehyde (&#x000b1;)-trans-<bold>8</bold> in THF at a low temperature selectively yielded the desired alcohol (&#x000b1;)-trans-<bold>10</bold>. The resulting product was then easily hydrogenated until saturated to obtain (&#x000b1;)-trans-<bold>11</bold>, and &#x003b1;-methylenation of the resulting lactone using Greene&#x02019;s procedure yielded compound <bold>UB033</bold>.</p><list list-type="simple"><list-item><p>Synthesis of <bold>UB034</bold></p></list-item></list><p>The synthesis of <bold>UB034</bold> was initiated through the Grignard addition of vinyl magnesium bromide to aldehyde (&#x000b1;)-trans-<bold>8</bold> at &#x02212;20 &#x000b0;C to produce allylic alcohol (&#x000b1;)-trans-<bold>12</bold> in moderate yield. The improved performance of this addition compared with previous experiments using butyl or hexyl magnesium bromides is likely attributable to the milder character of vinyl metal reagents. Finally, &#x003b1;-methylenation using Greene&#x02019;s procedure of the resulting lactone generated a sample of the compound <bold>UB034</bold>.</p><list list-type="simple"><list-item><p>Synthesis of <bold>UB035</bold></p></list-item></list><p>Treatment of allylic alcohol (&#x000b1;)-trans-<bold>12</bold> with ozone followed by reduction with NaBH<sub>4</sub> facilitated the isolation of diol (&#x000b1;)-trans-<bold>13</bold> as a mixture of stereoisomers. Further &#x003b1;-methylenation of the resulting compound using Greene&#x02019;s procedure produced compound <bold>UB035</bold>.</p><list list-type="simple"><list-item><p>Synthesis of <bold>UB036</bold></p></list-item></list><p>Triol (&#x000b1;)-trans-<bold>14</bold> was easily obtained following a well-known procedure using Os(VIII) oxide dihydroxylation of (&#x000b1;)-trans-<bold>12</bold> as a mixture of stereoisomers. Subsequent &#x003b1;-methylenation of the resulting lactone using Greene&#x02019;s procedure produced <bold>UB036</bold>.</p></sec><sec id="sec2dot2-pharmaceuticals-18-00194"><title>2.2. Cytotoxic Effects on the OVCAR-3 Cell Line</title><p>Fatty acids are an important source of energy in cells. Thus, FAS is a relevant target enzyme in rapidly proliferating tissues, such as in cancer [<xref rid="B16-pharmaceuticals-18-00194" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-18-00194" ref-type="bibr">17</xref>]. To test the anti-tumor activity of the newly synthesized (&#x000b1;)-<bold>UB006</bold> derivatives, cytotoxicity assays were performed in the commonly used ovarian cancer cell line, OVCAR3 (<xref rid="pharmaceuticals-18-00194-f002" ref-type="fig">Figure 2</xref>). An MTT cytotoxic assay showed that (&#x000b1;)-<bold>UB031</bold> and (&#x000b1;)-<bold>UB035</bold> were better cytotoxic agents than (&#x000b1;)-<bold>UB006</bold>, while (&#x000b1;)-<bold>UB036</bold> maintained a comparable effect. (&#x000b1;)-<bold>UB031</bold> and (&#x000b1;)-<bold>UB035</bold> showed 1.4-fold (IC50 = 3.6 &#x000b1; 0.2 &#x000b5;M) and 2.5-fold (IC50 = 2.1 &#x000b1; 0.2 &#x000b5;M) increases in cytotoxicity, respectively, compared with (&#x000b1;)-<bold>UB006</bold> (IC50 = 5.0 &#x000b1; 0.6 &#x000b5;M). We previously showed that racemic and (&#x02013;) enantiomers of <bold>UB006</bold> are better cytotoxic agents than racemic <bold>C75</bold> [<xref rid="B18-pharmaceuticals-18-00194" ref-type="bibr">18</xref>]. Differences in the cytotoxic capacity of (&#x000b1;)-<bold>UB006</bold> were observed between the present results and our previous findings [<xref rid="B18-pharmaceuticals-18-00194" ref-type="bibr">18</xref>]. This discrepancy could be due to differences in the passage of the OVCAR3 cell line used, which may have caused partial dedifferentiation, subsequently affecting the cells&#x02019; susceptibility to the compounds.</p></sec><sec id="sec2dot3-pharmaceuticals-18-00194"><title>2.3. Effect of (&#x000b1;)-<italic toggle="yes"><bold>UB006</bold></italic> and Its Derivatives on FAS Activity</title><p>The inhibitory effect of (&#x000b1;)-<bold>C75</bold> on FAS has been previously described by our group (IC50 = 460 &#x000b1; 56 &#x000b5;M) [<xref rid="B5-pharmaceuticals-18-00194" ref-type="bibr">5</xref>]. Here, we analyzed the effect of racemic mixtures of (&#x000b1;)-<bold>UB006</bold>, and its derivatives, (&#x000b1;)-<bold>UB035</bold> and (&#x000b1;)-<bold>UB036,</bold> on FAS activity. All exhibited comparable FAS inhibitory activity (<xref rid="pharmaceuticals-18-00194-f003" ref-type="fig">Figure 3</xref>), with IC50 values of 458 &#x000b1; 49 &#x000b5;M, 565 &#x000b1; 62 &#x000b5;M, and 458 &#x000b1; 54 &#x000b5;M, respectively. This indicates that the enhanced cytotoxic activity observed for (&#x000b1;)-<bold>UB035</bold> compared with (&#x000b1;)-<bold>UB006</bold> (<xref rid="pharmaceuticals-18-00194-f002" ref-type="fig">Figure 2</xref>) was not attributable to differences in FAS inhibition (<xref rid="pharmaceuticals-18-00194-f003" ref-type="fig">Figure 3</xref>).</p></sec><sec id="sec2dot4-pharmaceuticals-18-00194"><title>2.4. Thermodynamic Solubility Assessment of (&#x000b1;)-<italic toggle="yes"><bold>UB006</bold></italic> and Its Derivatives</title><p>The solubility of (&#x000b1;)-<bold>UB006</bold> and its derivatives was assessed through turbidimetry using water and 1% DMSO as the solvent and after a 2 h incubation at 37 &#x000b0;C with each compound (<xref rid="pharmaceuticals-18-00194-t002" ref-type="table">Table 2</xref>). Turbidimetric analysis showed a biphasic curve, presenting an inflection point at which the compounds failed to solubilize. This effectively created two regression lines, with the intersection corresponding to the solubility of the compound.</p><p>The thermodynamic solubility of (&#x000b1;)-<bold>UB006</bold> was estimated to be 550 &#x000b5;M. Elongation of the carbon chain led to progressive loss of solubility, with solubility values of 473 &#x000b5;M, 390 &#x000b5;M, and 76 &#x000b5;M for (&#x000b1;)-<bold>UB031</bold>, (&#x000b1;)-<bold>UB032</bold>, and (&#x000b1;)-<bold>UB033</bold>, respectively. The compound (&#x000b1;)-<bold>UB034</bold> showed a dramatic decrease in solubility (88 &#x000b5;M) compared with (&#x000b1;)-<bold>UB032</bold>, which was likely attributable to the loss of free rotation of the double bond. Derivatives (&#x000b1;)-<bold>UB035</bold> and (&#x000b1;)-<bold>UB036</bold> were soluble at all tested concentrations (25&#x02013;2000 &#x000b5;M), presenting at least a 4-fold increase in solubility compared with (&#x000b1;)-<bold>UB006</bold>. Importantly, although the increase in solubility of both (&#x000b1;)-<bold>UB035</bold> and (&#x000b1;)-<bold>UB036</bold> did not change FAS activity compared to (&#x000b1;)-<bold>UB006</bold> (<xref rid="pharmaceuticals-18-00194-f003" ref-type="fig">Figure 3</xref>), it might have contributed to their enhanced cytotoxicity in ovarian cancer cells (<xref rid="pharmaceuticals-18-00194-f002" ref-type="fig">Figure 2</xref>).</p></sec></sec><sec id="sec3-pharmaceuticals-18-00194"><title>3. Materials and Methods</title><sec id="sec3dot1-pharmaceuticals-18-00194"><title>3.1. Synthesis of (&#x000b1;)-<italic toggle="yes"><bold>UB006</bold></italic> Derivatives</title><list list-type="simple"><list-item><p>Dimethyl 2-nonanoylsuccinate, (&#x000b1;)-<bold>2</bold></p></list-item></list><p>CoCl<sub>2</sub> (0.6 g, 4.6 mmol) was added to a mixture of dimethyl maleate (5 mL, 40 mmol) and n-nonanal (50 mL, 290 mmol). The resulting mixture was stirred for 16 h at 25 &#x000b0;C under a dry O<sub>2</sub> flow. The reaction mixture was treated with ethyl acetate (AcOEt; 200 mL) and washed with aqueous saturated NaHCO<sub>3</sub> (2 &#x000d7; 200 mL). The organic layer was dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. The crude extract was purified through flash chromatography (hexane/CH<sub>2</sub>Cl<sub>2</sub>, 1:1) to yield the desired product (21.94 g, 22.85 mmol, 96%). Oil; Rf = 0.63 (hexane: CH<sub>2</sub>Cl<sub>2</sub> 2:8); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz): &#x003b4; 3.99 (dd, J = 6.3, 8.2, 1H), 3.74 (s, 3H), 3.68 (s, 3H), 2.98 (dd, J = 8.2, 17.6, 1H), 2.84 (dd, J = 6.3, 17.6, 1H), 2.75&#x02013;2.57 (m, 2H), 1.64&#x02013;1.27 (m, 12H), 0.88 (t, J = 6.8, 3H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 101 MHz): &#x003b4; 204.1, 172.0, 169.2, 54.0, 52.9, 52.2, 43.0, 32.4, 32.0, 29.5, 29.3, 29.2, 23.6, 22.8, 14.3; IR (film): 2954, 2927, 2856, 1741, 1720, 1457, 1437, 1410, 1367, 1262, 1634, 1012, 668.</p><p>(2SR,3RS)-Methyl 2-octyl-5-oxotetrahydrofuran-3-carboxylate, (&#x000b1;)-<italic toggle="yes">trans</italic>-3 (HRMS (ESI+) calculated for C<sub>14</sub>H<sub>28</sub>O<sub>4</sub> [M + H]+ = 257.1747, found = 257.1746) and (2SR,3RS)-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid, (&#x000b1;)-<italic toggle="yes">trans</italic>-4 (HRMS (ESI+) calculated for C<sub>13</sub>H<sub>22</sub>NaO<sub>4</sub> [M + Na]+ = 265.1410, found = 265.1410) were synthesized following the procedures previously described [<xref rid="B18-pharmaceuticals-18-00194" ref-type="bibr">18</xref>].</p><list list-type="simple"><list-item><p>(2RS,3RS)-N-methoxy-N-methyl-2-octyl-5-oxotetrahydrofuran-3-carboxamide, (&#x000b1;)-<italic toggle="yes">trans-</italic><bold>5</bold></p></list-item></list><p>A solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>4</bold> (3.65 g, 15.12 mmol), EDC (4.23 g, 27.22 mmol), and DMAP (1.85 g, 15.12 mmol) was stirred in CH<sub>2</sub>Cl<sub>2</sub> (35 mL) at 0 &#x000b0;C for 30 min. Then, a solution of N,O-dimethylhydroxylamine (2.95 g, 30.24 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) was added. The mixture was stirred overnight at room temperature. Then, the mixture was quenched with brine (20 mL) and extracted with AcOEt (3 &#x000d7; 30 mL). Afterwards, combined organic phases were dried (MgSO<sub>4</sub>) and concentrated under reduced pressure. Purification of the residue through flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>) yielded the desired product (3.3 g, 11.56 mmol, 75%). Oil; Rf = 0.61 (CH<sub>2</sub>Cl<sub>2</sub>:AcOEt 9:1); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 4.66 (m, 1H), 3.70 (s, 3H), 3.39 (m, 1H), 3.22 (s, 3H), 2.86 (dd, J = 9.4, 17.5, 1H), 2.73 (dd, J = 9.4, 17.5, 1H), 1.78 (m, 2H), 1.56&#x02013;1.28 (m, 12H), 0.88 (t, J = 6.7, 3H); &#x003b4; <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 175.0, 171.5, 82.4, 61.6, 42.8, 35.2, 33.0, 32.4, 31.8, 29.4, 29.3, 29.2, 25.3, 22.7, 14.1; IR (film): 2924, 2854, 1774, 1659, 1463, 1450, 1177, 1006. MS (ESI+) calculated for C<sub>15</sub>H<sub>27</sub>NO<sub>4</sub> = 286.2 [M + H]+, found = 286.2.</p><list list-type="simple"><list-item><p>(2SR,3RS)-4-((RS)-1-hydroxyethyl)-5-octyldihydrofuran-2(3H)-one, (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>6</bold></p></list-item></list><p>A solution of methylmagnesium bromide in diethyl ether (Et<sub>2</sub>O; 395 &#x000b5;L, 1.19 mmol) was slowly added to a solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>5</bold> (308 mg, 1.08 mmol) in anhydrous THF (6 mL) at &#x02212;20 &#x000b0;C under N<sub>2</sub>. The mixture was stirred for 30 min at &#x02212;20 &#x000b0;C and then allowed to warm up to room temperature overnight. The reaction mixture was quenched with aqueous saturated NH<sub>4</sub>Cl (4 mL) and extracted with AcOEt (3 &#x000d7; 15 mL). Afterwards, combined organic phases were dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. NaBH<sub>4</sub> (21 mg, 0.55 mmol) was added to a stirred solution of the crude extract in MeOH (3 mL) at 0 &#x000b0;C, and the mixture was warmed to room temperature. After 1 h, the mixture was quenched with phosphate buffer pH 7 (5 mL) and extracted with AcOEt (3 &#x000d7; 10 mL). Afterwards, combined organic phases were dried (MgSO<sub>4</sub>) and concentrated under reduced pressure. Purification of the residue through flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/AcOEt 6:4) yielded the desired product, which was a mixture of stereoisomers (0.115 g, 0.47 mmol, 44%). Oil; Rf = 0.30 (CH<sub>2</sub>Cl<sub>2</sub>/AcOEt 6:4); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 4.53&#x02013;4.37 (m, 1H), 3.93&#x02013;3.73 (m, 1H), 2.70&#x02013;2.58 (dd, J = 18.0, 7.7, 1H), 2.58&#x02013;2.29 (dd, J = 18.0, 9.6, 1H), 2.22&#x02013;2.12 (m, 1H), 1.82&#x02013;1.16 (m, 14H), 1.21 (s, 3H), 0.88 (t, J = 6.7, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 177.2, 176.9, 83.2, 82.7, 69.2, 66.5, 47.4, 47.0, 36.2, 35.2, 31.9, 31.8, 31.6, 29.4, 29.3, 29.2, 25.5, 22.6, 21.8, 14.1. MS (ESI+) calculated for C<sub>14</sub>H<sub>27</sub>O<sub>3</sub> = 243.2 [M + H]+, found = 243.2.</p><p>(4SR,5SR)-4-(Hydroxymethyl)-5-octyldihydrofuran-2(3H)-one, (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>7</bold> (HRMS (ESI+) calculated for C<sub>13</sub>H<sub>25</sub>O<sub>3</sub> [M + H]+ = 229.1798, found = 229.1797) and (2SR,3RS)-2-octyl-5-oxotetrahydrofuran-3-carbaldehyde, (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>8</bold> (HRMS (ESI+) calculated for C<sub>13</sub>H<sub>23</sub>O<sub>3</sub> [M + H]+ = 227.1638, found = 227.1642) were synthesized following the procedures previously described [<xref rid="B18-pharmaceuticals-18-00194" ref-type="bibr">18</xref>].</p><list list-type="simple"><list-item><p>(2SR,3RS)-4-((RS)-1-hydroxypropyl)-5-octyldihydrofuran-2(3H)-one, (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>9</bold></p></list-item></list><p>Diethylzinc (1 M) in heptane (6.6 mL, 6.6 mmol) was slowly added to a solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>8</bold> (217 mg, 0.95 mmol) and (+)-N-methylephedrine (10 mg, 6% mol) in anhydrous hexane (3 mL) at 0 &#x000b0;C under N<sub>2</sub>. The mixture was stirred for 16 h, warming up to room temperature. The reaction mixture was quenched with aqueous HCl 1N (10 mL) and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 15 mL). Afterwards, combined organic phases were dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. Purification of the residue through flash chromatography (hexane/AcOEt, 7:3) produced the desired product as a mixture of stereoisomers (54 mg, 0.21 mmol, 22%). Oil; Rf = 0.42 (hexane/AcOEt 7:3); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 4.41&#x02013;4.33 (m, 1H), 3.69&#x02013;3.61 (m, 1H), 2.70&#x02013;2.60 (dd, J = 18.0, 7.7, 1H), 2.52&#x02013;2.40 (dd, 1H), 2.25&#x02013;2.14 (m, 1H), 1.82&#x02013;1.16 (m, 16H), 1.03 (t, J = 7.4, 3H), 0.88 (t, J = 6.7, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 177.1, 83.9, 70.2, 45.8, 35.8, 31.8, 29.5, 29.4, 29.2, 29.0, 28.0, 25.8, 22.7, 14.1, 9.8. MS (ESI+) calculated for C<sub>14</sub>H<sub>27</sub>O<sub>3</sub> [M + H]+ = 242.2, found = 242.1.</p><list list-type="simple"><list-item><p>(2SR,3RS)-4-((RS)-1-hydroxyhept-2-yn-1-yl)-5-octyldihydrofuran-2(3H)-one, (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>10</bold></p></list-item></list><p>BuLi (1.6 M) in hexane (0.65 mL, 1.05 mmol) was slowly added to a solution of 1-hexyne (133 &#x000b5;L, 1.16 mmol) in anhydrous THF (3 mL) under N<sub>2</sub>. The mixture was stirred for 30 min at &#x02212;78 &#x000b0;C. A solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-8, 240 mg, 1.05 mmol) in THF was added at &#x02212;78 &#x000b0;C, and the mixture was then stirred for 2 h at 0 &#x000b0;C. The reaction was quenched with saturated aqueous NH<sub>4</sub>Cl (4 mL) and extracted with hexane/AcOEt 9:1 (3 &#x000d7; 10 mL). Afterwards, the combined organic phases were dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. Purification of the residue through flash chromatography (hexane/AcOEt 8:2) yielded the desired product as a mixture of stereoisomers (0.14 g, 0.45 mmol, 43%). Oil; Rf = 0.55 (hexane/AcOEt 8:2); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 4.55&#x02013;4.44 (m, 1H), 4.42&#x02013;4.38 (m, 1H), 2.67&#x02013;2.61 (m, 1H), 2.60&#x02013;2.5. (dd, J = 18.0, 7.7, 1H), 2.46&#x02013;2.40 (dd, J = 18.0, 9.6, 1H), 2.23&#x02013;2.18 (m, 2H), 1.80&#x02013;1.20 (m, 19H), 0.94&#x02013;0.88 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 176.3, 88.3, 88.0, 82.2, 82.0, 78.0, 63.5, 63.1, 46.2, 35.7, 31.8, 30.9, 30.4, 29.7, 29.4, 29.3, 25.3, 22.6, 21.9, 18.2, 14.1, 13.5. MS (ESI+) calculated for C<sub>19</sub>H<sub>33</sub>O<sub>3</sub> [M + H]+ = 309.2, found = 309.2.</p><list list-type="simple"><list-item><p>(2SR,3RS)-4-(1-hydroxyheptyl)-5-octyldihydrofuran-2(3H)-one, (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>11</bold></p></list-item></list><p>A solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>10</bold> (91 mg, 0.30 mmol) in AcOEt (5 mL) was treated with 5% Pd/C under H<sub>2</sub>, and the suspension was shaken for 5 h at room temperature. The mixture was filtered through Celite<sup>&#x000ae;</sup>, and the solid was washed with AcOEt. Afterwards, combined organic phases were dried (MgSO<sub>4</sub>) and concentrated under reduced pressure to produce the desired product as a mixture of stereoisomers (92 mg, 0.29 mmol, 99%). Oil; Rf = 0.23 (CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 4.54&#x02013;4.39 (m, 1H), 3.68&#x02013;3.54 (m, 1H), 2.71&#x02013;2.59 (m, 1H), 2.51&#x02013;2.41 (dd, J = 18.0, 7.7, 1H), 2.39&#x02013;2.30 (dd, J = 18.0, 9.6, 1H), 2.23&#x02013;2.14 (m, 1H), 1.80&#x02013;1.20 (m, 23H), 0.94&#x02013;0.88 (m, 6H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 177.2, 177.0, 83.0, 82.8, 73.3, 70.1, 46.3, 45.6, 36.3, 35.8, 35.39, 35.14, 31.8, 31.7, 29.7, 29.6, 29.48, 29.45, 29.42, 29.37, 29.23, 29.18, 29.15, 28.9, 25.8, 25.58, 25.52, 25.50, 22.6,22.5, 14.1, 14.0. MS (ESI+) calculated for C<sub>19</sub>H<sub>37</sub>O<sub>3</sub> [M + H]+ = 313.3, found = 313.2.</p><list list-type="simple"><list-item><p>(2SR,3RS)-4-((RS)-1-hydroxyallyl)-5-octyldihydrofuran-2(3H)-one, (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>12</bold></p></list-item></list><p>Vinylmagnesium bromide (1 M) THF solution (5.2 mL, 5.2 mmol) was slowly added to a solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>8</bold> (1.18 g, 4.38 mmol) in anhydrous THF in N<sub>2</sub> atm. (15 mL). The mixture was stirred at &#x02212;78 &#x000b0;C for 1 h and allowed to warm to room temperature overnight. The reaction mixture was quenched with aqueous 1 N HCl (10 mL) and extracted with hexane/AcOEt 9:1 (3 &#x000d7; 20 mL). Afterwards, combined organic phases were dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. Purification of the residue through flash chromatography (hexane/AcOEt 8:2) yielded the desired product as a mixture of stereoisomers (0.223 g, 0.87 mmol, 20%). Oil; Rf = 0.45 (hexane/AcOEt 7:3); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 5.87&#x02013;5.75 (ddd, J = 10.4, 6.5, 1.4 Hz, 1H), 5.38&#x02013;5.29 (dd, J = 3.3, 1.2 Hz, 1H), 5.29&#x02013;5.24 (dt, J = 3.29, 1.17, 1H), 4.19&#x02013;4.07 (m, 1H), 3.93&#x02013;3.73 (m, 1H), 2.67&#x02013;2.33 (dd, J = 18.0, 7.7, 1H), 2.59&#x02013;2.53 (dd, J = 18.0, 9.6, 1H), 2.33&#x02013;2.24 (m, 1H), 1.82&#x02013;1.16 (m, 14H), 0.88 (t, J = 6.7, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 176.7, 176.6, 138.0, 117.6, 117.4, 82.5, 82.1, 74.4, 72.6, 69.2, 66.4, 45.4, 44.9, 36.0, 35.3, 31.8, 31.3, 29.6, 29.4, 29.3, 29.2, 25.4, 22.6, 14.1. MS (ESI+) calculated for C<sub>15</sub>H<sub>27</sub>O<sub>3</sub> [M + H]+ = 255.2, found = 255.2.</p><list list-type="simple"><list-item><p>(2SR,3RS)-4-(1,2-dihydroxyethyl)-5-octyldihydrofuran-2(3H)-one, (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>13</bold></p></list-item></list><p>A stream of ozone gas was passed through a solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>11</bold> (456 mg, 1.79 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) at &#x02212;78 &#x000b0;C until blue coloration persisted. Then, a stream of N<sub>2</sub> was passed through the mixture for 2 min, and NaBH<sub>4</sub> (339 mg, 8.96 mmol) and MeOH (20 mL) were added to the mixture and stirred for 1 h at room temperature. The mixture was quenched with saturated aqueous NH<sub>4</sub>Cl (20 mL) and brine (20 mL). The combined aqueous phases were extracted with EtOAc (3 &#x000d7; 50 mL). Afterwards, combined organic phases were dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. Purification of the residue through flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 98:2) gave the desired diol as a mixture of stereoisomers (187 mg, 0.72 mmol, 40%). Oil; Rf = 0.29 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 95:5); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): &#x003b4; 4.47&#x02013;4.31 (m, 1H), 3.58&#x02013;3.45 (m, 1H), 3.42&#x02013;3.31 (m, 2H), 2.62&#x02013;2.53 (dd, J = 18.0, 7.7, 1H), 2.43&#x02013;2.33 (dd, J = 18.0, 9.6, 1H), 2.33&#x02013;2.24 (m, 1H), 1.82&#x02013;1.16 (m, 14H), 0.88 (t, J = 6.7, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 178.2, 178.0, 83.4, 83.2, 73.2, 69.8, 64.1, 64.0, 36.2, 35.7, 34.5, 31.6, 29.1, 29.0, 28.9, 25.3, 22.3, 13.0. MS (ESI+) calculated for C<sub>14</sub>H<sub>27</sub>O<sub>4</sub> [M + H]+ = 259.2, found = 259.3.</p><list list-type="simple"><list-item><p>(2SR,3RS)-5-octyl-4-(1,2,3-trihydroxypropyl)dihydrofuran-2(3H)-one, (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>14</bold></p></list-item></list><p>A solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>12</bold> (100 mg, 0.39 mmol) in THF (4 mL) was added to a solution of K<sub>2</sub>OsO<sub>4</sub> (5% mol) and 4-methylmorpholine N-oxide (105 mg, 0.78 mmol) in H<sub>2</sub>O/acetone (1:1, 8 mL). The mixture was stirred at room temperature overnight. Then, the mixture was filtered, and HCl 0.5N (10 mL) was added and extracted with AcOEt (3 &#x000d7; 15 mL). The combined organic phases were washed with HCl 1N (40 mL) and dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. Flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 94:6) of the residue allowed us to obtain the desired triol as a mixture of stereoisomers (0.122 g, 0.42 mmol, 66%). Oil; Rf = 0.26 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 98:2); <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): &#x003b4; 4.64&#x02013;4.38 (m, 1H), 3.80&#x02013;3.70 (m, 1H), 3.60&#x02013;3.50 (m, 2H), 3.48&#x02013;3.31 (m, 1H), 2.80&#x02013;2.42 (m, 3H), 1.86&#x02013;1.20 (m, 14H), 0.88 (t, J = 6.7, 3H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 182.7, 182.5, 87.4, 86.5, 76.9, 76.8, 76.7, 73.1, 67.5, 67.4, 46.5, 45.6, 39.8, 38.4, 35.9, 35.6, 33.2, 33.1, 33.0, 32.9, 31.9, 29.3, 29.2, 26.3, 17.0. MS (ESI+) calculated for C<sub>15</sub>H<sub>29</sub>O<sub>5</sub> [M + H]+ = 289.2, found = 289.0.</p><list list-type="simple"><list-item><p>Typical methylenation procedure (using CO<sub>2</sub>)</p></list-item><list-item><p>(4RS,5SR)-4-(hydroxymethyl)-3-methylene-5-2(octyldihydrofuran3H)-one, (&#x000b1;)-<bold>UB006</bold></p></list-item></list><p>A 0.5 M LDA solution in THF (1.5 mL, 0.75 mmol) was slowly added to a stirred solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>7</bold> (0.127 g, 0.6 mmol) in THF (5 mL) at &#x02212;20 &#x000b0;C under N2. After 3 h at &#x02212;20 &#x000b0;C, a CO<sub>2</sub> (from solid CO<sub>2</sub>) flow was passed through the mixture for 30 min. The mixture was acidified with 6 N HCl to pH 2 and diluted with H<sub>2</sub>O (10 mL). The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). The combined organic phases were dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. The resulting brown residue was treated with a freshly prepared solution of acetic acid (1.03 mL), formalin (0.93 mL), sodium acetate (AcONa; 0.055 g), and N-methylaniline (0.52 mL), and the mixture was stirred for 2 h at room temperature. Then, 10 mL of saturated aqueous NaCl and concentrated HCl (1 mL) were added. After 5 min, the resulting residue was thoroughly extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). The organic extracts were washed with brine, dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. Purification of the residue through flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>) yielded the desired product (72 mg, 0.315 mmol, 52%). Oil; Rf = 0.35 (CH<sub>2</sub>Cl<sub>2</sub>:MeOH 98:2); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 6.33 (d, J = 2.4, 1H), 5.71 (d, J = 2.4, 1H), 4.43&#x02013;4.36 (m, 1H), 3.76 (dd, J = 6.4, 2.1, 2H), 2.91&#x02013;2.83 (m, 1H), 1.87&#x02013;1.59 (m, 2H), 1.55&#x02013;1.17 (m, 12H), 0.88 (t, J = 6.9, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 170.5, 136.4, 123.6, 80.9, 64.1, 47.0, 36.2, 31.9, 29.5, 29.4, 29.3, 25.1, 22.8, 14.2. HRMS (ESI+) calculated for C<sub>14</sub>H<sub>24</sub>O<sub>3</sub> [M + H]+ = 241.1798, found = 241.1793.</p><list list-type="simple"><list-item><p>Typical methylenation procedure (using MMC)</p></list-item><list-item><p>(4RS,5SR)-4-(1-hydroxyethyl)-3-methylene-5-octyldihydrofuran-2(3H)-one, (&#x000b1;)-<bold>UB031</bold></p></list-item></list><p>A mixture of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>6</bold> (0.135 g, 0.85 mmol) and 2 M dimethylmagnesium carbonate (MMC) in DMF (9.75 mL, 19.5 mmol) was stirred at 135 &#x000b0;C under N<sub>2</sub> for 48 h. Subsequently, the solution was cooled to room temperature, and 6 N HCl (20 mL) and CH<sub>2</sub>Cl<sub>2</sub> (20 mL) were carefully added. The layers were decanted, and the aqueous layer was extracted with further CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). Then, the combined organic extracts were washed with aqueous saturated NaCl (50 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. The resulting brown residue was treated with 3.5 mL of a freshly prepared solution of acetic acid (1.55 mL), formalin (1.48 mL), AcONa (0.05 g), and N-methylaniline (0.482 mL) and stirred at room temperature for 2 h. The reaction mixture was then treated with 10 mL of aqueous saturated NaCl and 1 mL of concentrated HCl. After 5 min, the resulting residue was thoroughly extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). The organic extracts were washed with brine (30 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. Purification of the residue through flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>) yielded a sample of the desired product (16 mg, 0.067 mmol, 8%). Oil; Rf = 0.31 (CH<sub>2</sub>Cl<sub>2</sub>:MeOH 98:2); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 6.37 (d, J = 2.4, 1H), 5.73 (d, J = 2.4, 1H), 4.54 (m, 1H), 3.94 (m, 1H), 2.67 (m, 1H), 1.68&#x02013;1.55 (m, 2H), 1.55&#x02013;1.17 (m, 15H), 0.88 (t, J = 6.9, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 170.3, 136.4, 124.3, 79.3, 69.0, 51.4, 36.7, 31.8, 29.4, 29.3, 29.2, 25.0, 22.6, 20.1, 14.1. HRMS (ESI+) calculated for C<sub>15</sub>H<sub>27</sub>O<sub>3</sub> [M + H]+ = 255.1955, found = 255.1958.</p><list list-type="simple"><list-item><p>Preparation of (&#x000b1;)-<bold>UB032</bold></p></list-item><list-item><p>(4RS,5SR)-4-(1-hydroxypropyl)-3-methylene-5-octyldihydrofuran-2(3H)-one, (&#x000b1;)-<bold>UB032</bold></p></list-item></list><p>A mixture of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>9</bold> (0.230 g, 0.85 mmol) and 2 M dimethylmagnesium carbonate (MMC) in DMF (9.75 mL, 19.5 mmol) was stirred at 135 &#x000b0;C under N<sub>2</sub> for 48 h. After cooling to room temperature, 6 N HCl (20 mL) and CH<sub>2</sub>Cl<sub>2</sub> (20 mL) were added carefully to the solution. The layers were separated, and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). Then, the combined organic extracts were washed with NaCl (50 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. The resulting brown residue was treated with 3.5 mL of a freshly prepared solution of acetic acid (1.55 mL), formalin (1.48 mL), AcONa (0.05 g), and N-methylaniline (0.482 mL) and stirred at room temperature for 2 h. The reaction mixture was then treated with 10 mL of aqueous saturated NaCl and 1 mL of concentrated HCl. After 5 min, the resulting residue was carefully extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). The organic extracts were washed with brine (30 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. Purification of the residue through flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>) yielded a sample of the desired product as a mixture of stereoisomers (16 mg, 0.067 mmol, 8%). Oil; Rf = 0.31 (CH<sub>2</sub>Cl<sub>2</sub>:MeOH 98:2); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 6.35 (d, J = 2.4, 1H), 5.68 (d, J = 2.4, 1H), 4.58 (m, 1H), 3.66 (m, 1H), 2.71 (m, 1H), 1.64&#x02013;1.49 (m, 2H), 1.50&#x02013;1.41 (m, 2H), 1.55&#x02013;1.17 (m, 12H), 1.00 (t, J = 7.0, 3H), 0.88 (t, J = 6.9, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 170.4, 137.0, 123.8, 79.1, 74.6, 50.0, 36.8, 31.7, 29.4, 29.3, 29.2, 26.8, 25.0, 22.7, 14.1, 10.1. HRMS (ESI+) calculated for C<sub>16</sub>H<sub>29</sub>O<sub>3</sub> [M + H]+ = 269.2111, found = 269.2118.</p><list list-type="simple"><list-item><p>Preparation of (&#x000b1;)-<bold>UB033</bold></p></list-item><list-item><p>(4RS,5SR)-4-(1-hydroxyheptyl)-3-methylene-5-octyldihydrofuran-2(3H)-one, (&#x000b1;)-<bold>UB033</bold></p></list-item></list><p>A 2 M solution of THF LDA (0.73 mL, 1.47 mmol) was slowly added to a solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>11</bold> (0.092 g, 0.29 mmol) in THF (5 mL) at &#x02212;20 &#x000b0;C under N<sub>2</sub>, and the mixture was stirred for 3 h. A stream of CO<sub>2</sub> (from solid CO<sub>2</sub>) was passed through the mixture for 30 min. The mixture was acidified with 6 N HCl to pH 2 and diluted with H<sub>2</sub>O (10 mL). The aqueous phase was extracted using CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). The combined organic phases were dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. The resulting brown residue was treated with 1.2 mL of a freshly prepared solution of acetic acid (0.5 mL), formalin (0.456 mL), AcONa (0.026 g), and N-methylaniline (0.255 mL) and stirred at room temperature for 2 h. The reaction mixture was then treated with 10 mL of aqueous saturated NaCl and 10 M HCl (1 mL). After 5 min, the resulting residue was thoroughly extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). The organic extracts were washed with brine, dried (MgSO<sub>4</sub>), and concentrated under reduced pressure. Purification of the residue through flash chromatography (hexane/Et2O 6:4) yielded a sample of the desired product as a mixture of stereoisomers (5 mg, 0.015 mmol, 5%). Oil; Rf = 0.35 (hexane/Et2O 1:1); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 6.38 (d, J = 2.4, 1H), 5.69 (d, J = 2.4, 1H), 4.57 (m, 1H), 3.75 (m, 1H), 2.72 (m, 1H), 1.64&#x02013;1.49 (m, 2H), 1.50&#x02013;1.41 (m, 2H), 1.55&#x02013;1.17 (m, 12H), 1.43 (s, 3H), 0.88 (t, J = 6.9, 3H) 0.92&#x02013;0.80 (m, 8H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 170.3, 137.0, 123.8, 79.0, 73.2, 50.3, 36.7, 33.7, 31.8, 31.7, 30.3, 29.7, 29.4, 29.3, 29.2, 29.1, 25.7, 24.9, 22.6, 14.1. HRMS (ESI+) calculated for C<sub>20</sub>H<sub>37</sub>O<sub>3</sub> [M + H]+ = 325.2737, found = 325.2747.</p><list list-type="simple"><list-item><p>Preparation of (&#x000b1;)-<bold>UB034</bold></p></list-item><list-item><p>(4RS,5SR)-4-(1-hydroxyallyl)-3-methylene-5-octyldihydrofuran-2(3H)-one, (&#x000b1;)-<bold>UB034</bold></p></list-item></list><p>A 2 M solution of THF LDA (1.3 mL, 2.6 mmol) was slowly added to a solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>12</bold> (0.136 g, 0.53 mmol) in THF (5 mL) at &#x02212;20 &#x000b0;C under N<sub>2</sub>, and the mixture was stirred for 3 h. A stream of CO<sub>2</sub> (from solid CO<sub>2</sub>) was passed through the mixture for 30 min. The mixture was acidified with 6 N HCl to pH 2 and diluted with H<sub>2</sub>O (10 mL). The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). The combined organic phases were dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. The resulting brown residue was treated with 2.2 mL of a freshly prepared solution of acetic acid (0.91 mL), formalin (0.82 mL), AcONa (0.048 g), and N-methylaniline (0.46 mL) and stirred at room temperature for 2 h. The reaction mixture was then treated with 10 mL of aqueous saturated NaCl and concentrated HCl (1 mL). After 5 min, the resulting residue was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). The organic extracts were washed with brine, dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. Purification of the residue through flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>) yielded the desired product as a mixture of stereoisomers (23 mg, 0.086 mmol, 16%). Oil; Rf = 0.15 (CH<sub>2</sub>Cl<sub>2</sub>); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 6.35 (t, J = 2.4, 1H), 5.87&#x02013;5.70 (m, 2H), 5.35&#x02013;5.32 (dt, J = 2.4, 1.3, 1H), 5.31&#x02013;5.26 (m, 1H), 4.54&#x02013;4.38 (m, 1H), 4.25&#x02013;4.17 (m, 1H), 2.85&#x02013;2.75 (m, 1H), 1.64&#x02013;1.56 (m, 2H), 1.55&#x02013;1.17 (m, 12H), 0.88 (t, J = 6.9, 3H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 170.3, 170.1, 136.9, 136.6, 135.8, 135.4, 124.9, 124.6, 118.2, 118.1, 79.5, 79.2, 74.4, 74.3, 49.6, 49.5, 36.5, 36.3, 31.8, 29.3, 29.2, 29.1, 24.9, 24.8, 22.6, 14.1. HRMS (ESI+) calculated for C<sub>16</sub>H<sub>27</sub>O<sub>3</sub> [M + H]+ = 267.1955, found = 267.1953.</p><list list-type="simple"><list-item><p>Preparation of (&#x000b1;)-<bold>UB035</bold></p></list-item><list-item><p>(4RS,5SR)-4-((RS)-1,2-dihydroxyethyl)-3-methylene-5-octyldihydrofuran-2(3H)-one, (&#x000b1;)-<bold>UB035</bold></p></list-item></list><p>A 2 M solution of THF LDA (1.82 mL, 3.64 mmol) was slowly added to a stirred solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>13</bold> (0.189 g, 0.73 mmol) in THF (5 mL) under N<sub>2</sub> at &#x02212;20 &#x000b0;C. After 3 h, a stream of CO<sub>2</sub> (from solid CO<sub>2</sub>) was passed through the mixture for 30 min. The mixture was acidified with 6 N HCl to pH 2 and diluted with H<sub>2</sub>O (10 mL). The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). The combined organic phases were dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. The resulting brown residue was treated with 3 mL of a freshly prepared solution of acetic acid (1.25 mL), formalin (1.13 mL), AcONa (0.065 g), and N-methylaniline (0.632 mL) and stirred at room temperature for 2 h. The reaction mixture was then treated with 10 mL of saturated NaCl and concentrated HCl (1 mL). After 5 min, the resulting residue was thoroughly extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). The organic extracts were washed with brine, dried (MgSO<sub>4</sub>), and concentrated under reduced pressure. Purification of the residue through flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 99:1) yielded the desired product as a mixture of stereoisomers (43 mg, 0.16 mmol, 22%). Oil; Rf = 0.25 (CH<sub>2</sub>Cl<sub>2</sub>:MeOH 95:5); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 6.19 (d, J = 2.4, 1H), 5.70 (d, J = 2.4, 1H), 4.58 (m, 1H), 3.62 (m, 1H), 3.47 (m, 2H), 2.87 (m, 1H), 1.52 (m, 2H), 1.55&#x02013;1.17 (m, 12H), 0.88 (t, J = 6.9, 3H); <sup>13</sup>C NMR (101 MHz, CD<sub>3</sub>OD): &#x003b4; 171.2, 137.6, 122.9, 79.2, 73.2, 46.8, 36.1, 31.6, 29.1, 29.0, 28.9, 26.8, 24.6, 22.3, 13.0. HRMS (ESI+) calculated for C<sub>15</sub>H<sub>27</sub>O<sub>4</sub> [M + H]+ = 271.1904, found = 271.1912.</p><list list-type="simple"><list-item><p>Preparation of (&#x000b1;)-<bold>UB036</bold></p></list-item><list-item><p>(4RS,5SR)-3-methylene-5-octyl-4-(1,2,3-trihydroxypropyl)dihydrofuran-2(3H)-one, (&#x000b1;)-<bold>UB036</bold></p></list-item></list><p>A solution of (&#x000b1;)-<italic toggle="yes">trans</italic>-<bold>14</bold> (0.134 g, 0.46 mmol) and 2 M solution of dimethylmagnesium carbonate (MMC) in DMF (8.13 mL, 16.2 mmol) was stirred at 135 &#x000b0;C under N<sub>2</sub> for 48 h. Subsequently, the solution was cooled to room temperature and 6 N HCl (20 mL) and CH<sub>2</sub>Cl<sub>2</sub> (20 mL) were added carefully. The layers were decanted, and the aqueous layer was extracted with additional CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). Then, the combined organic extracts were washed with aqueous saturated NaCl (50 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. The resulting brown residue was treated with 3.5 mL of a freshly prepared solution of acetic acid (1.29 mL), formalin (1.23 mL), AcONa (0.042 g), and N-methylaniline (0.402 mL) and stirred at room temperature for 2 h. The reaction mixture was then treated with 10 mL of saturated aqueous NaCl and 1 mL of concentrated HCl. After 5 min, the resulting residue was thoroughly extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 &#x000d7; 20 mL). The organic extracts were washed with brine (30 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated under reduced pressure. Purification of the residue through flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 94:6) produced the desired product as a mixture of stereoisomers (70 mg, 0.24 mmol, 53%). Oil; Rf = 0.2 (CH<sub>2</sub>Cl<sub>2</sub>/MeOH 94:6); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): &#x003b4; 6.15 (s, 1H), 5.57 (s, 1H), 4.55 (m, 1H), 3.67&#x02013;3.27 (m, 4H), 2.97 (m, 1H), 1.55&#x02013;1.17 (m, 12H), 0.88 (t, J = 6.9, 3H) <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): &#x003b4; 172.5, 172.4, 138.9, 135.7, 125.3, 123.3, 82.6, 79.6, 74.7, 73.5, 72.0, 71.4, 64.4, 47.0, 46.9, 37.0, 36.6, 33.2, 33.1, 32.9, 29.3, 25.4, 25.3, 14.3. HRMS (ESI+) calculated for C<sub>16</sub>H<sub>29</sub>O<sub>5</sub> [M + H]+ = 301.2010, found = 301.2020.</p></sec><sec id="sec3dot2-pharmaceuticals-18-00194"><title>3.2. Cell Culture and Viability Assays</title><p>OVCAR-3 (human ovary carcinoma, ATC HTB-161, passage number 20) cells were cultured at 37 &#x000b0;C in a humidified atmosphere of 5% CO<sub>2</sub> in Dulbecco&#x02019;s Modified Eagle Medium containing 4.5 g/L of glucose and supplemented with glutamine, 10% heat-inactivated fetal bovine serum, 100 units/mL of penicillin, and 100 mg/mL of streptomycin. The culture was passaged twice a week through gentle trypsinization. Cells were seeded in 10 cm culture dishes and grown to confluence. An MTT cytotoxicity assay was performed to evaluate the cytotoxic effect of the compounds. A total of 2 &#x000d7; 103 cells/well were plated in 96-well plates in 100 mL of culture medium. After 24 h, the medium was removed, and cells were incubated for 72 h in fresh medium with different concentrations (0.5&#x02013;20 &#x000b5;M) of the different compounds. DMSO was used as a blank at a final concentration of 0.5%. The cells were then incubated for 3 h with 100 mL of fresh medium and 20 mL of MTT dissolved in phosphate-buffered saline to a final concentration of 5 mg/mL. Following treatment, the supernatants were carefully removed, and the MTT&#x02013;formazan crystals were solubilized by adding 100 mL/well of DMSO. The absorbance was measured at 570 nm.</p></sec><sec id="sec3dot3-pharmaceuticals-18-00194"><title>3.3. Turbidimetry Assay</title><p>The compound (&#x000b1;)-<bold>UB006</bold> and its derivatives were dissolved in 300 &#x000b5;L of milliQ-water at 1% DMSO in a 96-well plate to concentrations ranging from 25 to 2000 &#x000b5;M. The compounds were incubated for 2 h at 37 &#x000b0;C in a Thermoshaker (Biosan<sup>&#x000ae;</sup>, Riga, Latvia). Solubility was assessed through turbidimetry at 600 nm using Varioskan Lux<sup>&#x000ae;</sup> (Thermo Scientific<sup>&#x000ae;</sup>, Waltham, MA, USA). The approximate solubility was calculated by finding the intersection of the two regression lines formed before and after the curve tendency change due to precipitation of the compounds.</p></sec><sec id="sec3dot4-pharmaceuticals-18-00194"><title>3.4. FAS Activity</title><p>For in vitro experiments, FAS was purified from rat liver following the protocol previously described by Linn [<xref rid="B19-pharmaceuticals-18-00194" ref-type="bibr">19</xref>]. FAS activity was measured using a spectrophotometric method, as previously described [<xref rid="B20-pharmaceuticals-18-00194" ref-type="bibr">20</xref>]. Cytosolic hepatic extracts obtained from rat (210 &#x000b5;g) were preincubated at 30 &#x000b0;C for 30 min in a 96-well plate with increasing concentrations of the following, (&#x000b1;)-<bold>UB006</bold>, (&#x000b1;)-<bold>UB035</bold>, and (&#x000b1;)-<bold>UB036</bold> dissolved in DMSO (100&#x02013;5000 mM), using DMSO as a blank. The remaining derivatives were not tested based on cytotoxicity results obtained in the MTT assay. NADPH (121 &#x000b5;M) and acetyl-CoA (61 &#x000b5;M) in potassium phosphate buffer (pH 7.2) were added to preincubated enzyme and equilibrated at 37 &#x000b0;C for 3 min. The reaction was initiated through the addition of malonyl-CoA (55 &#x000b5;M). The total reaction volume was 330 &#x000b5;L. Oxidation of NADPH was measured at 340 nm at 37 &#x000b0;C for 10 min.</p></sec><sec id="sec3dot5-pharmaceuticals-18-00194"><title>3.5. Statistical Analysis</title><p>Data are expressed as the mean &#x000b1; SEM. Data processing was assessed using linear regression and non-linear variable slope regression. Statistical analysis was assessed using one-way ANOVA. GraphPad Prism 10.0 was used for data representation.</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceuticals-18-00194"><title>4. Conclusions</title><p>We aimed to identify more potent and soluble anti-cancer compounds by synthesizing several derivatives of (&#x000b1;)-<bold>UB006</bold> via elongation of the carbon chain of the primary alcohol and/or the addition of hydroxyl groups. We have accomplished the synthesis of a family of highly soluble (&#x000b1;)-<bold>UB006</bold> derivatives that show promising activity as anti-cancer agents. We conclude that (&#x000b1;)-<bold>UB035</bold> showed higher cytotoxic activity and solubility than (&#x000b1;)-<bold>UB006</bold>. Remarkably, while incorporation of an ethyl secondary hydroxyl group to (&#x000b1;)-<bold>UB006</bold> did not display a higher inhibitory effect on FAS activity, it significantly increased the in vitro antitumor effects against the ovarian cancer cell line, OVCAR3. This addition also dramatically improved solubility, which is a major shortcoming of <bold>C75</bold> and previously synthesized derivatives, and it also created a new stereocenter. It has been described that FAS inhibitors trigger cell death through apoptotic mechanisms [<xref rid="B21-pharmaceuticals-18-00194" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-18-00194" ref-type="bibr">22</xref>]. In fact, we have previously shown that the mechanisms through which (&#x02212;)-<bold>UB006</bold> exerts its cytotoxic effect on the OVCAR-3 cell line include a decrease in mitochondrial respiratory capacity and ATP production, an upregulation of the energy stress factor DDIT4/REDD1, mTOR activity inhibition, and caspase-3 activation, leading to apoptosis [<xref rid="B18-pharmaceuticals-18-00194" ref-type="bibr">18</xref>]. DDIT4/REDD1 is known to inhibit the mTOR pathway and cell proliferation [<xref rid="B23-pharmaceuticals-18-00194" ref-type="bibr">23</xref>]. The cytotoxicity effect of the new (&#x000b1;)-<bold>UB006</bold> derivatives described here might involve similar mechanisms that finally trigger cancer cell apoptosis. Both (&#x000b1;)-<bold>UB035</bold> and (&#x000b1;)-<bold>UB036</bold> derivatives showed higher solubility compared to (&#x000b1;)-<bold>UB006</bold> (<xref rid="pharmaceuticals-18-00194-t002" ref-type="table">Table 2</xref>). Although this increase in solubility did not change FAS&#x02019;s inhibitory effects compared to (&#x000b1;)-<bold>UB006</bold>, it might have contributed to their enhanced cytotoxicity in the ovarian cancer cells tested. Future research should include the study of (&#x000b1;)-<bold>UB035</bold> stereoisomers in vivo. However, we believe that their effects will likely correlate with those of (&#x000b1;)-<bold>UB006</bold>. Furthermore, the stereoisomers derived from this new chiral center may show different cytotoxicity, and further investigation into these compounds is required for the treatment of cancer.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, J.G., L.H., X.A., and D.S.; methodology, M.R.; formal analysis, M.R.; writing&#x02014;review and editing, M.R., J.G., and L.H.; supervision, J.G., L.H., X.A., and D.S.; funding acquisition, D.S. and L.H. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data generated during the study are available from the corresponding author upon reasonable request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">AMP</td><td align="left" valign="middle" rowspan="1" colspan="1">Adenosine monophosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ATP</td><td align="left" valign="middle" rowspan="1" colspan="1">Adenosine triphosphate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DBU</td><td align="left" valign="middle" rowspan="1" colspan="1">1,8-Diazabicyclo(5.4.0)undec-7-ene</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DDIT4/REDD1</td><td align="left" valign="middle" rowspan="1" colspan="1">DNA-damage-inducible transcript 4/regulated in development and DNA damage responses 1 protein</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DIPEA</td><td align="left" valign="middle" rowspan="1" colspan="1">Diisopropylethylamine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DMAP</td><td align="left" valign="middle" rowspan="1" colspan="1">4-Dimethylaminopyridine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DMHA</td><td align="left" valign="middle" rowspan="1" colspan="1">N,O-dimethylhydroxylamine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DMSO</td><td align="left" valign="middle" rowspan="1" colspan="1">Dimethyl sulfoxide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DOAJ</td><td align="left" valign="middle" rowspan="1" colspan="1">Directory of open access journals</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EDC</td><td align="left" valign="middle" rowspan="1" colspan="1">1-ethyl-3-carbodiimide</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FAS</td><td align="left" valign="middle" rowspan="1" colspan="1">Fatty acid synthase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IC50</td><td align="left" valign="middle" rowspan="1" colspan="1">50% Inhibition concentration </td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LD</td><td align="left" valign="middle" rowspan="1" colspan="1">Linear dichroism</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDPI</td><td align="left" valign="middle" rowspan="1" colspan="1">Multidisciplinary Digital Publishing Institute</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MMC</td><td align="left" valign="middle" rowspan="1" colspan="1">Methyl magnesium carbonate</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">mTOR</td><td align="left" valign="middle" rowspan="1" colspan="1">mammalian target of rapamycin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NMA</td><td align="left" valign="middle" rowspan="1" colspan="1">N-methylaniline</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TEA</td><td align="left" valign="middle" rowspan="1" colspan="1">Triethylamine</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">THF</td><td align="left" valign="middle" rowspan="1" colspan="1">Tetrahydrofuran</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-18-00194"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jones</surname><given-names>S.F.</given-names></name>
<name><surname>Infante</surname><given-names>J.R.</given-names></name>
<name><surname>Pathways</surname><given-names>M.</given-names></name>
</person-group><article-title>Molecular Pathways: Fatty Acid Synthase</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>5434</fpage><lpage>5438</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0126</pub-id><pub-id pub-id-type="pmid">26519059</pub-id>
</element-citation></ref><ref id="B2-pharmaceuticals-18-00194"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pizer</surname><given-names>E.S.</given-names></name>
<name><surname>Wood</surname><given-names>F.D.</given-names></name>
<name><surname>Heine</surname><given-names>H.S.</given-names></name>
<name><surname>Romantsev</surname><given-names>F.E.</given-names></name>
<name><surname>Pasternack</surname><given-names>G.R.</given-names></name>
<name><surname>Kuhajda</surname><given-names>F.P.</given-names></name>
</person-group><article-title>Inhibition of Fatty Acid Synthesis Delays Disease Progression in a Xenograft Model of Ovarian Cancer1</article-title><source>Cancer Res.</source><year>1996</year><volume>56</volume><fpage>1189</fpage><lpage>1193</lpage><pub-id pub-id-type="pmid">8640795</pub-id>
</element-citation></ref><ref id="B3-pharmaceuticals-18-00194"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pizer</surname><given-names>E.S.</given-names></name>
<name><surname>Chrest</surname><given-names>F.J.</given-names></name>
<name><surname>Digiuseppe</surname><given-names>J.A.</given-names></name>
<name><surname>Han</surname><given-names>W.F.</given-names></name>
</person-group><article-title>Pharmacological Inhibitors of Mammalian Fatty Acid Synthase Suppress DNA Replication and Induce Apoptosis in Tumor Cell Lines1</article-title><source>Cancer Res.</source><year>1998</year><volume>58</volume><fpage>4611</fpage><lpage>4615</lpage><pub-id pub-id-type="pmid">9788612</pub-id>
</element-citation></ref><ref id="B4-pharmaceuticals-18-00194"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ruiz-P&#x000e9;rez</surname><given-names>M.V.</given-names></name>
<name><surname>Sainero-Alcolado</surname><given-names>L.</given-names></name>
<name><surname>Oliynyk</surname><given-names>G.</given-names></name>
<name><surname>Matuschek</surname><given-names>I.</given-names></name>
<name><surname>Balboni</surname><given-names>N.</given-names></name>
<name><surname>Ubhayasekera</surname><given-names>S.J.K.A.</given-names></name>
<name><surname>Snaebjornsson</surname><given-names>M.T.</given-names></name>
<name><surname>Makowski</surname><given-names>K.</given-names></name>
<name><surname>Aaltonen</surname><given-names>K.</given-names></name>
<name><surname>Bexell</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Inhibition of fatty acid synthesis induces differentiation and reduces tumor burden in childhood neuroblastoma</article-title><source>IScience</source><year>2021</year><volume>24</volume><fpage>102128</fpage><pub-id pub-id-type="doi">10.1016/j.isci.2021.102128</pub-id><pub-id pub-id-type="pmid">33659885</pub-id>
</element-citation></ref><ref id="B5-pharmaceuticals-18-00194"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Makowski</surname><given-names>K.</given-names></name>
<name><surname>Mera</surname><given-names>P.</given-names></name>
<name><surname>Paredes</surname><given-names>D.</given-names></name>
<name><surname>Herrero</surname><given-names>L.</given-names></name>
<name><surname>Ariza</surname><given-names>X.</given-names></name>
<name><surname>Asins</surname><given-names>G.</given-names></name>
<name><surname>Hegardt</surname><given-names>F.G.</given-names></name>
<name><surname>Garc&#x000ed;a</surname><given-names>J.</given-names></name>
<name><surname>Serra</surname><given-names>D.</given-names></name>
</person-group><article-title>Differential pharmacologic properties of the two C75 enantiomers: (+)-C75 is a strong anorectic drug; (-)-C75 has antitumor activity</article-title><source>Chirality</source><year>2013</year><volume>25</volume><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1002/chir.22139</pub-id><pub-id pub-id-type="pmid">23620264</pub-id>
</element-citation></ref><ref id="B6-pharmaceuticals-18-00194"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>E.K.</given-names></name>
<name><surname>Miller</surname><given-names>I.</given-names></name>
<name><surname>Aja</surname><given-names>S.</given-names></name>
<name><surname>Landree</surname><given-names>L.E.</given-names></name>
<name><surname>Pinn</surname><given-names>M.</given-names></name>
<name><surname>McFadden</surname><given-names>J.</given-names></name>
<name><surname>Kuhajda</surname><given-names>F.P.</given-names></name>
<name><surname>Moran</surname><given-names>T.H.</given-names></name>
<name><surname>Ronnett</surname><given-names>G.V.</given-names></name>
</person-group><article-title>C75, a Fatty Acid Synthase Inhibitor, Reduces Food Intake via Hypothalamic AMP-activated Protein Kinase</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>19970</fpage><lpage>19976</lpage><pub-id pub-id-type="doi">10.1074/jbc.M402165200</pub-id><pub-id pub-id-type="pmid">15028725</pub-id>
</element-citation></ref><ref id="B7-pharmaceuticals-18-00194"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schroeder</surname><given-names>B.</given-names></name>
<name><surname>Steen</surname><given-names>T.V.</given-names></name>
<name><surname>Espinoza</surname><given-names>I.</given-names></name>
<name><surname>Venkatapoorna</surname><given-names>C.M.K.</given-names></name>
<name><surname>Hu</surname><given-names>Z.</given-names></name>
<name><surname>Silva</surname><given-names>F.M.</given-names></name>
<name><surname>Regan</surname><given-names>K.</given-names></name>
<name><surname>Cuy&#x000e0;s</surname><given-names>E.</given-names></name>
<name><surname>Meng</surname><given-names>X.W.</given-names></name>
<name><surname>Verdura</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells</article-title><source>Cell Death Dis.</source><year>2021</year><volume>12</volume><fpage>977</fpage><pub-id pub-id-type="doi">10.1038/s41419-021-04262-x</pub-id><pub-id pub-id-type="pmid">34675185</pub-id>
</element-citation></ref><ref id="B8-pharmaceuticals-18-00194"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Uddin</surname><given-names>S.</given-names></name>
<name><surname>Siraj</surname><given-names>A.K.</given-names></name>
<name><surname>Al-Rasheed</surname><given-names>M.</given-names></name>
<name><surname>Ahmed</surname><given-names>M.</given-names></name>
<name><surname>Bu</surname><given-names>R.</given-names></name>
<name><surname>Myers</surname><given-names>J.N.</given-names></name>
<name><surname>Al-Nuaim</surname><given-names>A.</given-names></name>
<name><surname>Al-Sobhi</surname><given-names>S.</given-names></name>
<name><surname>Al-Dayel</surname><given-names>F.</given-names></name>
<name><surname>Bavi</surname><given-names>P.</given-names></name>
<etal/>
</person-group><article-title>Fatty Acid Synthase and AKT Pathway Signaling in a Subset of Papillary Thyroid Cancers</article-title><source>J. Clin. Endocrinol. Metab.</source><year>2008</year><volume>93</volume><fpage>4088</fpage><lpage>4097</lpage><pub-id pub-id-type="doi">10.1210/jc.2008-0503</pub-id><pub-id pub-id-type="pmid">18682509</pub-id>
</element-citation></ref><ref id="B9-pharmaceuticals-18-00194"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wagner</surname><given-names>R.</given-names></name>
<name><surname>St&#x000fc;biger</surname><given-names>G.</given-names></name>
<name><surname>Veigel</surname><given-names>D.</given-names></name>
<name><surname>Wuczkowski</surname><given-names>M.</given-names></name>
<name><surname>Lanzerstorfer</surname><given-names>P.</given-names></name>
<name><surname>Weghuber</surname><given-names>J.</given-names></name>
<name><surname>Karteris</surname><given-names>E.</given-names></name>
<name><surname>Nowikovsky</surname><given-names>K.</given-names></name>
<name><surname>Wilfinger-Lutz</surname><given-names>N.</given-names></name>
<name><surname>Singer</surname><given-names>C.F.</given-names></name>
<etal/>
</person-group><article-title>Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>11600</fpage><lpage>11613</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.14591</pub-id><pub-id pub-id-type="pmid">28086243</pub-id>
</element-citation></ref><ref id="B10-pharmaceuticals-18-00194"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hu</surname><given-names>Z.</given-names></name>
<name><surname>Seung</surname><given-names>H.C.</given-names></name>
<name><surname>Van Haasteren</surname><given-names>G.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Lane</surname><given-names>M.D.</given-names></name>
</person-group><article-title>From the Cover: Effect of centrally administered C75, a fatty acid synthase inhibitor, on ghrelin secretion and its downstream effects</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>3972</fpage><pub-id pub-id-type="doi">10.1073/pnas.0500619102</pub-id><pub-id pub-id-type="pmid">15728730</pub-id>
</element-citation></ref><ref id="B11-pharmaceuticals-18-00194"><label>11.</label><element-citation publication-type="webpage"><article-title>MedChemExpress USA, C75 Product Data Sheet, HY-12364, 2024</article-title><comment>Available online: <ext-link xlink:href="https://www.medchemexpress.com/C75.html?srsltid=AfmBOopHHJWLP4b1cN2rdhFw8OLw3BbDhkzAsxpsPxt4QkGG9cX33806" ext-link-type="uri">https://www.medchemexpress.com/C75.html?srsltid=AfmBOopHHJWLP4b1cN2rdhFw8OLw3BbDhkzAsxpsPxt4QkGG9cX33806</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-27">(accessed on 27 January 2025)</date-in-citation></element-citation></ref><ref id="B12-pharmaceuticals-18-00194"><label>12.</label><element-citation publication-type="other"><person-group person-group-type="author">
<name><surname>Garc&#x000ed;a</surname><given-names>R.G.</given-names></name>
</person-group><article-title>Desarrollo y Evaluaci&#x000f3;n de An&#x000e1;logos de C75 Como Potenciales F&#x000e1;rmacos Contra la Obesidad y el C&#x000e1;ncer, 2023</article-title><comment>Available online: <ext-link xlink:href="https://www.tesisenred.net/handle/10803/689648#page=1" ext-link-type="uri">https://www.tesisenred.net/handle/10803/689648#page=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-01-27">(accessed on 27 January 2025)</date-in-citation></element-citation></ref><ref id="B13-pharmaceuticals-18-00194"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chudasama</surname><given-names>V.</given-names></name>
<name><surname>Fitzmaurice</surname><given-names>R.J.</given-names></name>
<name><surname>Caddick</surname><given-names>S.</given-names></name>
</person-group><article-title>Hydroacylation of &#x003b1;,&#x003b2;-unsaturated esters via aerobic C&#x02013;H activation</article-title><source>Nat. Chem.</source><year>2010</year><volume>2</volume><fpage>592</fpage><lpage>596</lpage><pub-id pub-id-type="doi">10.1038/nchem.685</pub-id><pub-id pub-id-type="pmid">20571580</pub-id>
</element-citation></ref><ref id="B14-pharmaceuticals-18-00194"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mutta</surname><given-names>M.M.</given-names></name>
<name><surname>de Azevedo</surname><given-names>M.B.M.</given-names></name>
<name><surname>Greene</surname><given-names>A.E.</given-names></name>
</person-group><article-title>An Improved Procedure for a-Methylenation of Lactones</article-title><source>Synth. Commun.</source><year>1993</year><volume>23</volume><fpage>495</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1080/00397919308009804</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-18-00194"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Soai</surname><given-names>K.</given-names></name>
<name><surname>Yokoyama</surname><given-names>S.</given-names></name>
<name><surname>Ebihara</surname><given-names>K.</given-names></name>
<name><surname>Hayasaka</surname><given-names>T.</given-names></name>
</person-group><article-title>A new chiral catalyst for the highly enantioselective addition of dialkylzinc reagents to aliphatic aldehydes</article-title><source>J. Chem. Soc. Chem. Commun.</source><year>1987</year><volume>22</volume><fpage>1690</fpage><lpage>1691</lpage><pub-id pub-id-type="doi">10.1039/c39870001690</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-18-00194"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>M.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
</person-group><article-title>The expanded role of fatty acid metabolism in cancer: New aspects and targets</article-title><source>Precis. Clin. Med.</source><year>2019</year><volume>2</volume><fpage>183</fpage><pub-id pub-id-type="doi">10.1093/pcmedi/pbz017</pub-id><pub-id pub-id-type="pmid">31598388</pub-id>
</element-citation></ref><ref id="B17-pharmaceuticals-18-00194"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fhu</surname><given-names>C.W.</given-names></name>
<name><surname>Ali</surname><given-names>A.</given-names></name>
</person-group><article-title>Fatty Acid Synthase: An Emerging Target in Cancer</article-title><source>Molecules</source><year>2020</year><volume>25</volume><elocation-id>3935</elocation-id><pub-id pub-id-type="doi">10.3390/molecules25173935</pub-id><pub-id pub-id-type="pmid">32872164</pub-id>
</element-citation></ref><ref id="B18-pharmaceuticals-18-00194"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Makowski</surname><given-names>K.</given-names></name>
<name><surname>Mir</surname><given-names>J.F.</given-names></name>
<name><surname>Mera</surname><given-names>P.</given-names></name>
<name><surname>Ariza</surname><given-names>X.</given-names></name>
<name><surname>Asins</surname><given-names>G.</given-names></name>
<name><surname>Hegardt</surname><given-names>F.G.</given-names></name>
<name><surname>Herrero</surname><given-names>L.</given-names></name>
<name><surname>Garc&#x000ed;a</surname><given-names>J.</given-names></name>
<name><surname>Serra</surname><given-names>D.</given-names></name>
</person-group><article-title>(-)-UB006: A new fatty acid synthase inhibitor and cytotoxic agent without anorexic side effects</article-title><source>Eur. J. Med. Chem.</source><year>2017</year><volume>131</volume><fpage>207</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2017.03.012</pub-id><pub-id pub-id-type="pmid">28324785</pub-id>
</element-citation></ref><ref id="B19-pharmaceuticals-18-00194"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Linn</surname><given-names>T.C.</given-names></name>
</person-group><article-title>Purification and crystallization of rat liver fatty acid synthetase</article-title><source>Arch. Biochem. Biophys.</source><year>1981</year><volume>209</volume><fpage>613</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1016/0003-9861(81)90320-9</pub-id><pub-id pub-id-type="pmid">7294812</pub-id>
</element-citation></ref><ref id="B20-pharmaceuticals-18-00194"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lelliott</surname><given-names>C.J.</given-names></name>
<name><surname>L&#x000f3;pez</surname><given-names>M.</given-names></name>
<name><surname>Curtis</surname><given-names>R.K.</given-names></name>
<name><surname>Parker</surname><given-names>N.</given-names></name>
<name><surname>Laudes</surname><given-names>M.</given-names></name>
<name><surname>Yeo</surname><given-names>G.</given-names></name>
<name><surname>Jimenez-Li&#x000f1;an</surname><given-names>M.</given-names></name>
<name><surname>Grosse</surname><given-names>J.</given-names></name>
<name><surname>Saha</surname><given-names>A.K.</given-names></name>
<name><surname>Wiggins</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis</article-title><source>FASEB J.</source><year>2005</year><volume>19</volume><fpage>1108</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1096/fj.04-3196com</pub-id><pub-id pub-id-type="pmid">15985534</pub-id>
</element-citation></ref><ref id="B21-pharmaceuticals-18-00194"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ventura</surname><given-names>R.</given-names></name>
<name><surname>Mordec</surname><given-names>K.</given-names></name>
<name><surname>Waszczuk</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>Z.</given-names></name>
<name><surname>Lai</surname><given-names>J.</given-names></name>
<name><surname>Fridlib</surname><given-names>M.</given-names></name>
<name><surname>Buckley</surname><given-names>D.</given-names></name>
<name><surname>Kemble</surname><given-names>G.</given-names></name>
<name><surname>Heuer</surname><given-names>T.S.</given-names></name>
</person-group><article-title>Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression</article-title><source>EBio-Medicine</source><year>2015</year><volume>2</volume><elocation-id>808e824</elocation-id><pub-id pub-id-type="doi">10.1016/j.ebiom.2015.06.020</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-18-00194"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>C.-S.</given-names></name>
<name><surname>Matsuura</surname><given-names>K.</given-names></name>
<name><surname>Huang</surname><given-names>N.-J.</given-names></name>
<name><surname>Robeson</surname><given-names>A.C.</given-names></name>
<name><surname>Huang</surname><given-names>B.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Kornbluth</surname><given-names>S.</given-names></name>
</person-group><article-title>Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death</article-title><source>Oncogene</source><year>2015</year><volume>34</volume><fpage>3264</fpage><lpage>3272</lpage><pub-id pub-id-type="doi">10.1038/onc.2014.271</pub-id><pub-id pub-id-type="pmid">25151963</pub-id>
</element-citation></ref><ref id="B23-pharmaceuticals-18-00194"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sofer</surname><given-names>A.</given-names></name>
<name><surname>Lei</surname><given-names>K.</given-names></name>
<name><surname>Johannessen</surname><given-names>C.M.</given-names></name>
<name><surname>Ellisen</surname><given-names>L.W.</given-names></name>
</person-group><article-title>Regulation of mTOR and cell growth in response to energy stress by REDD1</article-title><source>Mol. Cell. Biol.</source><year>2005</year><volume>25</volume><fpage>5834</fpage><lpage>5845</lpage><pub-id pub-id-type="pmid">15988001</pub-id>
</element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Schemes and Tables</title><fig position="float" id="pharmaceuticals-18-00194-f001"><label>Figure 1</label><caption><p>(&#x000b1;)-UB006 and its derivatives.</p></caption><graphic xlink:href="pharmaceuticals-18-00194-g001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00194-sch001"><object-id pub-id-type="pii">pharmaceuticals-18-00194-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p><bold>Synthesis of intermediates (&#x000b1;)-<italic toggle="yes">trans</italic>-6 and (&#x000b1;)-<italic toggle="yes">trans</italic>-8.</bold> (a) CoCl<sub>2</sub> cat, room temperature, 16 h, 96% yield. (b) NaBH<sub>4</sub>, MeOH, 0 &#x000b0;C, 1 h. (c) HCl cat., MeOH, reflux, 1 h. (d) 1,8-Diazabicyclo(5.4.0)undec-7-ene (DBU), toluene, reflux, 16 h. This produced a 60% yield for steps b, c, and d. (e) NaOH 1 N, THF, 70 &#x000b0;C, 1 h, 99% yield. (f) EDC, DMAP, N,O-dimethylhydroxylamine (DMHA), DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 0 &#x000b0;C, 16 h, 75% yield. (g) MeMgBr, THF, &#x02212;20 &#x000b0;C to room temperature, 12 h. (h) NaBH<sub>4</sub>, MeOH, 0 &#x000b0;C, 1 h. This produced a 44% yield for steps g and h. (i) BH<sub>3</sub>:SMe<sub>2</sub>, THF, &#x02212;20 &#x000b0;C 1 h, 0 &#x000b0;C 3 h, and room temperature overnight, 97% yield. (j) (COCl)<sub>2</sub>, DMSO, TEA, CH<sub>2</sub>Cl<sub>2</sub>, &#x02212;78 &#x000b0;C, 1 h, 70% yield.</p></caption><graphic xlink:href="pharmaceuticals-18-00194-sch001" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00194-sch002"><object-id pub-id-type="pii">pharmaceuticals-18-00194-sch002_Scheme 2</object-id><label>Scheme 2</label><caption><p><bold>Synthesis of lactones (&#x000b1;)-trans-11, (&#x000b1;)-trans-12, (&#x000b1;)-trans-13, and (&#x000b1;)-trans-14.</bold> (a) ZnEt<sub>2</sub>, (+)-N-methylephedrine, hexane, 0 &#x000b0;C, 16 h, 22% yield. (b) 1-hexyne, butyllithium, THF, &#x02212;78 &#x000b0;C to room temperature, 2 h, 43% yield. (c) Pd-C/H<sub>2</sub>, EtOAc, room temperature, 4 h, 99% yield. (d) Vinylmagnesium bromide, THF, &#x02212;20 &#x000b0;C to &#x02212;78 &#x000b0;C, 16 h, 20% yield. (e) O<sub>2</sub>/O<sub>3</sub>-, CH<sub>2</sub>Cl<sub>2</sub>, &#x02212;78 &#x000b0;C, 5 min. (f) NaBH<sub>4</sub>, MeOH, &#x02212;78 &#x000b0;C to room temperature, 1 h. This produced a 40% yield for steps e and f. (g) H<sub>2</sub>O&#x000b7;K<sub>2</sub>OsO<sub>4</sub>, H<sub>2</sub>O&#x000b7;4-methylmorpholine N-oxide, THF/acetone/H<sub>2</sub>O, room temperature, 16 h, 66% yield.</p></caption><graphic xlink:href="pharmaceuticals-18-00194-sch002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00194-sch003"><object-id pub-id-type="pii">pharmaceuticals-18-00194-sch003_Scheme 3</object-id><label>Scheme 3</label><caption><p><bold>General methylenation procedures to obtain (&#x000b1;)-UB006 derivatives.</bold> (a) Dimethylmagnesium carbonate (MMC), DMF, 135 &#x000b0;C, 48 h, 8&#x02013;53% yield. (b) LDA, CO<sub>2</sub>, THF, &#x02212;20 &#x000b0;C, 3.5 h. (c) N-methylaniline (NMA), formalin, AcOH/AcONa, room temperature, 2 h, 5&#x02013;52% yield.</p></caption><graphic xlink:href="pharmaceuticals-18-00194-sch003" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00194-f002"><label>Figure 2</label><caption><p><bold>Cytotoxicity of (&#x000b1;)-UB006 derivatives in the OVCAR-3 ovarian cancer cell line.</bold> Samples were incubated for 3 days with increasing concentrations of the different compounds, followed by an MTT assay to quantify cell survival. Results for (&#x000b1;)-UB006 are compared with (&#x000b1;)-UB032, (&#x000b1;)-UB033, and (&#x000b1;)-UB034 (<bold>left</bold>) and with (&#x000b1;)-UB031, (&#x000b1;)-UB035, and (&#x000b1;)-UB036 (<bold>right</bold>). Results are expressed as the average of three experiments &#x000b1;S.E.M.</p></caption><graphic xlink:href="pharmaceuticals-18-00194-g002" position="float"/></fig><fig position="float" id="pharmaceuticals-18-00194-f003"><label>Figure 3</label><caption><p><bold>FAS activity assay in rat liver extracts.</bold> Representation of % of remaining FAS activity of spectrophotometric activity assay. FAS-enriched (210 &#x003bc;g) hepatic extracts were incubated for 30 min at 30 &#x000b0;C with increasing concentrations of (&#x000b1;)-<bold>UB006</bold>, (&#x000b1;)-<bold>UB035</bold>, and (&#x000b1;)-<bold>UB036</bold>. Results are expressed as the average of three experiments &#x000b1; S.E.M.</p></caption><graphic xlink:href="pharmaceuticals-18-00194-g003" position="float"/></fig><table-wrap position="float" id="pharmaceuticals-18-00194-t001"><object-id pub-id-type="pii">pharmaceuticals-18-00194-t001_Table 1</object-id><label>Table 1</label><caption><p>(&#x000b1;)-<bold>UB006</bold> and its derivatives.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="middle" style=" border-bottom:solid thin" rowspan="1" colspan="1">
<inline-graphic xlink:href="pharmaceuticals-18-00194-i001.jpg"/>
</td><td align="center" valign="middle" style=" border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Compound</bold>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<bold>R</bold>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB006</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">-CH<sub>2</sub>OH</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB031</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">-CHOHCH<sub>3</sub></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB032</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">-CHOHCH<sub>2</sub>CH<sub>3</sub></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB033</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">-CHOH(CH<sub>2</sub>)<sub>6</sub>CH<sub>3</sub></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB034</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">-CHOHCH=CH<sub>2</sub></td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB035</bold></td><td align="center" valign="middle" rowspan="1" colspan="1">-CHOHCH<sub>2</sub>OH</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB036</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-CHOHCHOHCH<sub>2</sub>OH</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceuticals-18-00194-t002"><object-id pub-id-type="pii">pharmaceuticals-18-00194-t002_Table 2</object-id><label>Table 2</label><caption><p>Summary of cytotoxicity and solubility <sup>1</sup> of (&#x000b1;)-<bold>UB006</bold> derivatives.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">IC50 (&#x003bc;M)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">SOLUBILITY</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB006</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.0 &#x000b1; 0.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">550 &#x003bc;M</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB031</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.6 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">473 &#x003bc;M</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB032</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.7 &#x000b1; 0.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">390 &#x003bc;M</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB033</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13.6 &#x000b1; 1.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">76 &#x003bc;M</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB034</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.3 &#x000b1;1.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">88 &#x003bc;M</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB035</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.1 &#x000b1; 0.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;2 mM</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(&#x000b1;)-<bold>UB036</bold></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.5 &#x000b1; 0.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003e;2 mM</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Solubility was assessed based on the turbidimetry of increasing solutions of (&#x000b1;)-<bold>UB006</bold> derivatives. The tested concentrations were within 25 &#x003bc;M&#x02013;2 mM. Results are expressed as the average of three experiments &#x000b1; S.E.M.</p></fn></table-wrap-foot></table-wrap></sec></back></article>